Google
Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Endari: A Treatment Option for Sickle Cell Disease
source: Sickle Options
year: N/A
summary/abstract:Endari is an amino acid, approved by Food and Drug Administration (FDA) to treat sickle cell disease. It is available in powder form to be taken orally.
The exact mechanism of action of Endari is not fully understood but it increases the amount of free glutamine in the blood. Glutamine is used to make anti-oxidant molecules which reduce the oxidative stress in sickle red blood cells resulting in increased flexibility of red blood cells while they travel through the body.
Safety profile of Endari is not available for children less than 5 years of age and risk of taking Endari in pregnancy is not known yet.
read more
+myBinderRelated Content
-
L-glutamine Oral Powder Significantly Reduces Acute Complications of Sickle Cell DiseaseApproved by the US Food and Drug...
-
L-Glutamine for sickle cell anemia: More questions than answersIn 2017, the Food and Drug Administratio...
-
FDA Approves Glutamine Powder for Sickle Cell DiseaseThe U.S. Food and Drug Administration ap...
-
Emmaus, a leader in sickle cell disease treatment, signs agreement with McKesson to expand distribution network for ...Emmaus Life Sciences, Inc., anno...
-
Emmaus Life Sciences, Inc. to present results of phase 3 study of endariTM (L-glutamine oral powder) at 59th America...Emmaus will present results of a Phase 3...
-
Emmaus Life Sciences Receives Validation From European Medicines Agency on Marketing Authorization Application for S...Emmaus Life Sciences, Inc. announced tod...
-
FDA Advisory Committee Recommends Approval of Endari™ from Emmaus Life Sciences for the Treatment of Sickle Cell D...Emmaus Life Sciences Inc. announced toda...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.